OmniRayn
← All repurposing reports
S2 (505(b)(2))

IgA Nephropathy

Known, approved drugs ranked as repurposing candidates for IgA Nephropathy — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1mycophenolate mofetilApproved
  2. 2sildenafilApproved
  3. 3rucaparibApproved
  4. 4oxymetazolineApproved
  5. 5tubocurarineApproved
  6. 6mitoxantroneApproved
  7. 7phenazopyridineApproved
  8. 8erythromycin estolateApproved

Full dossier — 149 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950